Piper Sandler Downgrades Capricor Therapeutics (CAPR) to Neutral

July 30, 2026 2:52 AM

Piper Sandler analyst Edward Tenthoff downgraded Capricor Therapeutics (NASDAQ: CAPR) from Overweight to Neutral with a price target of $2.00 ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found